Wu JJ, et al. - Authors investigated if tumor necrosis factor inhibitor (TNFi) therapy was related to decreased major adverse cardiovascular events (MACE) in patients with psoriasis. Hazard ratios (HR) of MACE associated with TNFi use were assessed with propensity score-adjusted multivariable Cox regression. In patients with psoriasis receiving TNFi vs topical or oral/phototherapy agents, significantly lower MACE was noted. In mitigating cardiovascular event risk, TNFi therapy could have benefits beyond skin disease. Compared with the topical cohort, the oral/phototherapy cohort had similar MACE HR.